日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

Axicabtagene ciloleucel 与利妥昔单抗联合治疗难治性大 B 细胞淋巴瘤:2 期单臂 ZUMA-14 试验。

Strati Paolo, Leslie Lori, Shiraz Parveen, Budde Lihua E, Oluwole Olalekan O, Ulrickson Matthew, Ramakrishnan Aravind, Zhang Teresa, Sun Jennifer, Milletti Francesca, Kanska Justyna, Shen Rhine, Neumann Frank, Xu Hairong, Patel Krish

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 可独立预测 CD19 CAR-T 疗法治疗急性淋巴细胞白血病后的预后。

Valtis, Yannis K; Lin, Chenyu; Nemirovsky, David; Devlin, Sean; Rejeski, Kai; Curran, Kevin J; Wang, Xiuyan; Shah, Nirali N; Jeyakumar, Nikeshan; Miller, Katharine; Zhang, Amy; Kota, Vamsi K; Al Darobi, Ali H; Muhsen, Ibrahim; Sasine, Joshua; Aldoss, Ibrahim; Advani, Anjali S; Reshef, Ran; Chen, Evan C; Kopmar, Noam; Tsai, Stephanie B; Hilal, Talal; Shah, Bijal D; Faramand, Rawan; Solh, Melhem M; Tan, Virginia; Bezerra, Evandro; Battiwalla, Minoo; Ramakrishnan, Aravind; Mathews, John; Shaughnessy, Paul; Mountjoy, Luke; Hoeg, Rasmus T; Dykes, Kaitlyn C; Logan, Aaron C; Kumaran, Muthu V; Schwartz, Marc; Tracy, Sean; Moore, Jozal; Odstrcil Bobillo, Silvina; Frey, Noelle V; Connor, Matthew; Ladha, Abdullah; Dholaria, Bhagirathbhai; Sutherland, Katherine; Roloff, Gregory W; Muffly, Lori S; Park, Jae H

T(SCM)-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

以T(SCM)为主的异基因抗BCMA CAR-T疗法治疗复发/难治性多发性骨髓瘤:临床前特征及1期临床试验中期结果

Tseng, Hubert; Dholaria, Bhagirathbhai; Cranert, Stacey A; Richter, Maximilian; Marquez, Karl S; Cho, Benjamin S; Bacong, Andrew; McArthur, Katherine; Eskew, Jeff D; McCaigue, Joanne; Haag, Sabrina; Krasny, Aly; Solimine, Brian; Coffey, Michael J; Loyola, Aimee; Kwong, Jasmine; Shune, Leyla; Kin, Andrew; Costello, Caitlin L; Kocoglu, Mehmet H; Ramakrishnan, Aravind; Namini, Hamid; Martin, Christopher E; Belani, Rajesh; Coronella, Julia; Shedlock, Devon J

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

社区移植和细胞治疗网络中非霍奇金淋巴瘤抗CD19+ CAR-T疗法的获取障碍

Battiwalla, Minoo; Tees, Michael; Flinn, Ian; Pantin, Jeremy; Berdeja, Jesus; Gregory, Tara; Maris, Michael; Bhushan, Vikas; Vance, Estil; Mathews, John; Bachier, Carlos; Shaughnessy, Paul; Ramakrishnan, Aravind; Malik, Shahbaz; Mori, Shahram; Martin, Casey; Billups, Rocky; Blunk, Betsy; LeMaistre, Charles F; Majhail, Navneet S

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

利用双顺反子CAR-T细胞双重靶向CD19和CD22治疗复发/难治性大B细胞淋巴瘤患者

Roddie, Claire; Lekakis, Lazaros J; Marzolini, Maria A V; Ramakrishnan, Aravind; Zhang, Yiyun; Hu, Yanqing; Peddareddigari, Vijay G R; Khokhar, Nushmia; Chen, Robert; Basilico, Silvia; Raymond, Meera; Vargas, Frederick Arce; Duffy, Kevin; Brugger, Wolfram; O'Reilly, Maeve A; Wood, Leigh; Linch, David C; Peggs, Karl S; Bachier, Carlos; Budde, Elizabeth Lihua; Lee Batlevi, Connie; Bartlett, Nancy; Irvine, David; Tholouli, Eleni; Osborne, Wendy; Ardeshna, Kirit M; Pule, Martin A

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Belumosudil 用于既往接受过 2 线或以上治疗的慢性移植物抗宿主病:ROCKstar 研究

Cutler, Corey; Lee, Stephanie J; Arai, Sally; Rotta, Marcello; Zoghi, Behyar; Lazaryan, Aleksandr; Ramakrishnan, Aravind; DeFilipp, Zachariah; Salhotra, Amandeep; Chai-Ho, Wanxing; Mehta, Rohtesh; Wang, Trent; Arora, Mukta; Pusic, Iskra; Saad, Ayman; Shah, Nirav N; Abhyankar, Sunil; Bachier, Carlos; Galvin, John; Im, Annie; Langston, Amelia; Liesveld, Jane; Juckett, Mark; Logan, Aaron; Schachter, Levanto; Alavi, Asif; Howard, Dianna; Waksal, Harlan W; Ryan, John; Eiznhamer, David; Aggarwal, Sanjay K; Ieyoub, Jonathan; Schueller, Olivier; Green, Laurie; Yang, Zhongming; Krenz, Heidi; Jagasia, Madan; Blazar, Bruce R; Pavletic, Steven

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

SRSF2 突变通过突变特异性影响外显子识别而导致骨髓增生异常综合征

Kim, Eunhee; Ilagan, Janine O; Liang, Yang; Daubner, Gerrit M; Lee, Stanley C-W; Ramakrishnan, Aravind; Li, Yue; Chung, Young Rock; Micol, Jean-Baptiste; Murphy, Michele E; Cho, Hana; Kim, Min-Kyung; Zebari, Ahmad S; Aumann, Shlomzion; Park, Christopher Y; Buonamici, Silvia; Smith, Peter G; Deeg, H Joachim; Lobry, Camille; Aifantis, Iannis; Modis, Yorgo; Allain, Frederic H-T; Halene, Stephanie; Bradley, Robert K; Abdel-Wahab, Omar

Primary marrow-derived stromal cells: isolation and manipulation

原代骨髓间充质干细胞:分离和操作

Ramakrishnan, Aravind; Torok-Storb, Beverly; Pillai, Manoj M

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

阿扎胞苷和依那西普治疗MDS和CMML患者的疗效持久。

Scott, Bart L; Ramakrishnan, Aravind; Storer, Barry; Becker, Pamela S; Petersdorf, Steve; Estey, Elihu H; Deeg, H Joachim

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study

抗胸腺细胞球蛋白联合依那西普治疗骨髓增生异常综合征(MDS):一项II期研究

Scott, Bart L; Ramakrishnan, Aravind; Fosdal, Mark; Storer, Barry; Becker, Pamela; Petersdorf, Steve; Deeg, H Joachim